Background Pelvic organ prolapse is common and is strongly associated with childbirth and increasing age. Women with prolapse are often advised to do pelvic fl oor muscle exercises, but evidence supporting the benefi ts of such exercises is scarce. We aimed to establish the eff ectiveness of one-to-one individualised pelvic fl oor muscle training for reducing prolapse symptoms.
Introduction
Pelvic organ prolapse is a common disorder in women-40% of women older than 50 years have some degree of prolapse on examination. 1 About 11% of women undergo surgery for urinary incontinence or prolapse in their lifetime, and 7% for prolapse alone. 2 In England, about 29 000 prolapse repairs were done between 2010 and 2011, 3 at a cost of around £60 million, and numbers of women undergoing surgery are likely to increase substantially as the population ages. 4 Increasing age and parity, and a family history of prolapse, are the main risk factors for prolapse, although factors such as obesity, heavy lifting, and constipation can also have a role. 5 One study reported a total population-attributable risk for prolapse of 46%, which was associated with women having prolapse symptoms during pregnancy, a mother with prolapse, and undertaking heavy physical work. 6 Prolapse is characterised by symptomatic descent of the vaginal walls, apex, or vault from the normal anatomical position. 7 Women with prolapse might present with vaginal, bladder, bowel, back, abdominal, and sexual symptoms. The disorder can aff ect daily activity and quality of life. Treatment options include surgery and conservative management, of which the latter is used commonly if the prolapse is low in severity or the woman is not a candidate for surgery. Conservative interventions include physical interventions to improve the function and support of the pelvic fl oor muscles via pelvic fl oor muscle training; mechanical interventions (eg, use of vaginal pessaries) to support the prolapse; and lifestyle interventions (eg, weight loss and avoiding of heavy lifting) to avoid exacerbation of the prolapse by decreasing intra-abdominal pressure.
See Online for appendix
Many physiotherapists who specialise in women's health off er women with prolapse individualised pelvic fl oor muscle training. 8 The aim of muscle training is to improve the function of the pelvic fl oor muscles-ie, strength, endurance, and coordination-and to ultimately increase the structural support for the pelvic organs. A Cochrane review 9 showed that training of the pelvic fl oor muscles was eff ective for treatment of urinary incontinence. Evidence for the management of prolapse is less clear. A separate Cochrane review 10 identifi ed four trials (including two pilot trials) comparing individuals undergoing pelvic fl oor muscle training with control groups; two of which were at signifi cant risk of bias. Symptoms, although measured diff erently in diff erent studies, were improved in the short term in three trials, and pooled data for severity from two trials showed an improvement in prolapse after treatment due to muscle training. The review concluded that reliable evidence is needed about the medium-term and long-term eff ectiveness and cost-eff ectiveness of pelvic fl oor muscle training.
We did the Pelvic Organ Prolapse PhysiotherapY (POPPY) trial to assess whether one-to-one pelvic fl oor muscle training would reduce the symptoms of prolapse and the need for further prolapse treatment in women with stage I-III prolapse, and whether it would be a costeff ective option, compared with a prolapse lifestyle advice leafl et.
Methods

Study design and participants
We did this parallel-group, multicentre, randomised trial between June 22, 2007 , and April 9, 2010, in new attendees at outpatient gynaecology clinics who presented with symptomatic prolapse at 25 centres (23 in the UK; one in Dunedin, New Zealand; and one in Sydney, Australia). Centres were a mixture of university teaching hospitals and district general hospitals, and all off ered similar specialist pelvic fl oor physiotherapy services. Eligible women of any age had stage I-III prolapse of any type (anterior, posterior, apical, or a combination) as confi rmed by their gynaecologist on vaginal examination with the pelvic organ prolapse quantifi cation (POP-Q) system, 11 and had prolapse as their main presenting complaint. We excluded women who had received previous treatment for prolapse, including surgery; who were pregnant or less than 6 months postnatal; or who were unable to comply with the intervention (ie, if they were not able to attend the clinic for appointments with the physiotherapist). Women who needed treatment for vaginal atrophy were eligible after completing a course of local oestrogens.
We based the trial methods on fi ndings from our pilot trial. 12 Women provided signed informed consent. We did the trial in accordance with the Declaration of Helsinki. Approval was obtained from the Scotland A Research Ethics Committee, the Lower South Regional Ethics Committee, the Human Research Ethics Committees of The University of Melbourne, and from St George Hospital (Kogarah, NSW, Australia). An independent Trial Steering Committee and a separate independent Data Monitoring Committee oversaw the trial. Full details of the study protocol are available online.
Randomisation and masking
Patients were randomly assigned (1:1), with the remotecomputer-determined randomisation application at the Centre for Healthcare Randomised Trials (University of Aberdeen, UK), to receive an individualised programme of pelvic fl oor muscle training or a prolapse lifestyle advice leafl et and no muscle training (control group). Randomisation used a minimisation approach to balance group sizes for key prognostic factors at baseline. Factors were centre, stage of prolapse (I, II, or III), and the motivation for prolapse surgery (ie, women not considering surgery versus those considering surgery). Motivation for surgery is a potentially important factor aff ecting how adherent women will be to pelvic fl oor muscle training. The university-based trial coordinator accessed the web-based application and then informed the woman, and the physiotherapist as necessary, of the allocated group. The intervention could not be masked from women or treating physiotherapists. The researchers who coordinated data entry and management (SD, JL, GMcP) were remote from the clinical sites and therefore did not have contact with patients. Outcome assessment was by participant-completed questionnaires, thus avoiding assessor bias; data-entry staff were masked to group allocation. The gynaecologists undertaking the POP-Q assessment at 6 months, including those who were investigators (CG, KHM, and DW), were masked to group allocation until after the examination. The statistical analyst (SB) was independent of the research team and was masked to group allocation until after the main analysis had been undertaken.
Procedures
Women allocated to the intervention were invited to attend fi ve one-to-one appointments for pelvic fl oor muscle training over 16 weeks (at weeks 0, 2, 6, 11, and 16) with a women's health physiotherapist. The duration of 16 weeks was chosen on the basis of muscle physiology (15 weeks of specifi c muscle training is needed to gain muscle hypertrophy 13 ) and UK clinical guidelines for the management of urinary incontinence, which recommend muscle training for "at least 3 months".
14 Appointment frequency was based on present practice within the UK National Health Service (NHS)-ie, fi rst appointments close together to allow reinforcement of correct exercise technique and understanding of all advice given, later appointments becoming further apart to encourage independent home exercise.
At the fi rst appointment an explanation of types of prolapse, anatomy and function of pelvic fl oor muscles was given with use of diagrams and a model pelvis. Internal assessment of the pelvic fl oor muscles was done For the study protocol see https://w3.abdn.ac.uk/hsru/ poppy/Public/DownloadPage. aspx to correct exercise technique and assess muscles (using the PERFECT Scheme). 15 An individualised home exercise programme was prescribed on the basis of examination fi ndings. Women were encouraged to progress exercises, with an aim of ten times 10 s maximum holds and up to 50 fast contractions three times per day, and to record all exercises in a diary. Furthermore, women were taught how to precontract the pelvic fl oor muscles against increases in intra-abdominal pressure (so-called the Knack exercise) and were encouraged to use this technique daily. The home exercise programme was modifi ed at each appointment on the basis of examination fi ndings and diary recordings. Use of electromyography biofeedback, pressure biofeedback, and electrical stimulation were not permitted. Trial physiotherapists attended training before their involvement in intervention delivery within the trial. No additional training was given to physiotherapists during intervention delivery.
Participants received a prolapse lifestyle advice leafl et that gave advice about weight loss, constipation, avoidance of heavy lifting, coughing, and high-impact exercise; women in the control group received this leafl et by post, whereas women in the intervention group received it at their fi rst appointment. The leafl et contained no information about pelvic fl oor muscle exercises or techniques. Women attended a review appointment with their gynaecologist 6 months after trial entry, at which time they could be referred for further treatment if desired.
We used postal questionnaires to collect data at baseline, and 6 months and 12 months after trial entry. Our primary endpoint was prolapse symptoms at 12 months as measured by the pelvic organ prolapse symptom score (POP-SS), 16 a validated, patient-completed method with seven items relating to frequency of prolapse symptoms in the previous 4 weeks; each item is scored from 0 (never) to 4 (all of the time), with a possible total score ranging from 0 to 28. Secondary outcomes were women's perceived change in prolapse since the start of the study ( 19 use of health services in primary and secondary care; and frequency of the practice of pelvic fl oor muscle exercises in the past 4 weeks (a few times only, once a week, a few times a week, once a day, a few times a day; and contractions per day less than fi ve, fi ve to ten, 11-20, 21-30, 31-60, >60). Intervention adherence was measured in terms of attendance at appointments and the amount of exercise women recorded in their daily exercise diary. Additionally, at each appointment, the physiotherapists delivering the intervention collected data about women's adherence to the prescribed exercise.
The clinics' gynaecologists used the POP-Q system to assess prolapse type and stage in all women before group allocation and at the 6 month review appointment.
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Formal POP-Q training was given at each trial centre initiation visit. This training included a verbal explanation of the POP-Q system; observation of the American Urogynecological Society POP-Q training DVD; information about standardisation of conditions for POP-Q examination (eg, examination position, bladder emptying, and equipment use); and use of the recording form and a question and answer session. Each centre was given a copy of the DVD and the publication describing the POP-Q. 11 Centres were encouraged to undertake further in-house training, and additional centre visits were off ered if necessary.
Statistical analysis
We estimated a mean diff erence between groups in POP-SS of 2·5 (SD 8) as our eff ect size, on the basis of fi ndings from our pilot trial. 12 With 253 women per group, the trial had 80% power at a 5% signifi cance level to detect a diff erence of 2·5 points in the primary outcome measure, assuming a common SD of 8 points. 20 This calculation allowed for a 10% overall loss to follow-up, and 15% of the control group receiving all the benefi t of muscle training by undertaking exercises with their own initiative.
We tabulated descriptive statistics, reporting baseline demographics and clinical characteristics with means and SDs, or medians and IQRs as appropriate. We used intention-to-treat analyses to compare the primary outcome at 12 months by fi tting a linear mixed-eff ects model to change from baseline in POP-SS at 6 months and 12 months, with a random intercept for patient within centre, and a random slope for time within patient, and adjusted for baseline POP-SS score and the minimisation variables. Such models implicitly adjust the model estimates when data are missing, with an assumption that data are missing at random, according to reported values. 21 We included women who had observations at baseline and at least one follow-up timepoint in the model. We present the diff erence between the intervention and control groups in estimated mean change from baseline for 6 months and 12 months with 95% CIs and p values. We also used multiple imputation to assess the assumption of data missing at random and the corresponding eff ect of missing responses on the primary outcome. 22 Model assumptions were checked with residual plots and were shown to hold.
We compared POP-Q stage between groups in an ordinal regression model with 6 month POP-Q stage as the dependent variable and baseline POP-Q stage and minimisation variables as covariates. The pooled odds ratio (OR) from the ordinal model was calculated with a 95% CI and p value. Stage II prolapse was subdivided into two groups dependent on whether the prolapse was above the hymen or at the hymen or below. Change in POP-Q stage between baseline and 6 months was also presented. Other secondary outcomes were compared between groups with the Mann-Whitney U test for continuous and ordinal variables and the χ² or Fisher's exact test for categorical variables.
With planned subgroup analyses we explored the eff ect of prolapse stage and type, age, and motivation for surgery on the primary outcome, with stricter levels of signifi cance (two-sided p<0·01) than those used for other analyses.
Analyses were done according to a pre-specifi ed statistical analysis plan using the R programming package (version 2.15.0) 23 and the mi package in R (version 0.09-17) 24 for post-hoc multiple imputation analysis. Our economic assessment was a within-trial analysis 12 months after recruitment, with a cost perspective of the UK NHS. We used direct health-service costs to generate the total cost for each participant. On the basis of the number of physiotherapy appointments attended during the trial, we estimated the amount of physiotherapy time involved in the delivery of the intervention and the associated costs of clinic space. All women were asked in follow-up questionnaires about their use of health services (consultations with their family doctor or a practice nurse) and any further prolapse treatment they had received. Costs were attributed to these items with UK data from the Personal Social Services Research Unit, Unit Costs of Health and Social Care; Scottish Health Service Costs; British National Formulary; and C&G Medicare. [25] [26] [27] [28] The costs were balanced against changes in the primary clinical outcome. We assumed that diff erences between trial groups in rates of subsequent treatments, such as, surgery at the end of the trial follow-up period represented savings. We did sensitivity analyses to assess the possible eff ects of varying of the intervention eff ect size and the uptake of subsequent prolapse treatment.
This trial is registered, number ISRCTN35911035.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. GM, JN, SB, AE, SH, and AW had access to all the data in the study and all authors had fi nal responsibility for the decision to submit for publication.
Results
The fi gure shows the trial profi le. 447 eligible patients were randomised to the intervention group (n=225) or the control group (n=222). 377 (84%) participants completed follow-up for questionnaires at 6 months and 295 (66%) for questionnaires at 12 months (fi gure); 365 (82%) women attended for 6 month review. Non-responders at 12 months were signifi cantly younger and had a higher body-mass index (BMI) than did responders (data not shown). We noted no evidence of diff erential dropout between the trial groups (fi gure). Table 1 shows baseline clinical and demographic characteristics. The mean age of participants was 56·8 years (SD 11·5); the median number of births per woman was two (range zero to seven); 412 (93%) of 445 women had had at least one vaginal birth, 28 (6%) of 447 had had at least one caesarean section, 118 (26%) of 445 had had at least one forceps delivery, and 9 (2%) of 447 had had a vacuum extraction. Two (<1%) patients were missing the delivery type for a total of three births between them, explaining the denominator of 445 for these calculations. Women were on average overweight (mean BMI 27 [SD 5·1]). The most common presentation was combined anterior, posterior, and upper compartment Eight adverse events (six vaginal symptoms, one case of back pain and one of abdominal pain) and one unexpected serious adverse event (a skiing injury), defi ned as aff ecting normal daily life, were reported; all reports were from women in the intervention group. No event was deemed to be related to the intervention or to trial participation.
Women in the intervention group reported greater improvement in prolapse symptoms (a signifi cantly greater reduction in POP-SS) than those in the control group at both 6 months and 12 months (table 3) . When we combined the results from refi tting of the model to fi ve imputations of the missing POP-SS scores, estimates of the diff erences between the groups were very similar to those from the original model (6 months 2·79, 1·91-3·67; 12 months 1·66, 0·74-2·58). The most commonly reported symptom at baseline was "a feeling of something coming down" (table 1); this fi nding persisted at 6 months and 12 months (table 3). All POP-SS symptoms were signifi cantly less common in the intervention group than the control group at 6 months (table 3); at 12 months "discomfort worse when standing" and "lower abdominal heaviness" were signifi cantly less common (table 3) . Women in the intervention group were less likely than those in the control group to report prolapse symptoms in the last 4 weeks, both at 6 months and 12 months (table 3) .
When asked "how do you feel your prolapse is now compared to the start of the study?", women in the intervention group were signifi cantly more likely than those in the control group to report that their prolapse was "better", both at 6 months and 12 months (table 3) .
After adjustment for baseline POP-Q stage, centre, and whether the woman was motivated to have surgery, the odds of women having a low-severity of prolapse at 6 months were greater in the intervention group than in the control group, although this diff erence was not signifi cant (OR 1·47, 95% CI 0·97-2·27; p=0·07 Urinary incontinence score (ICIQ-UI SF §) 4 (0-7), n=218 4 (0-7), n=216
Data are mean (SD), median (IQR), n (%), or n/N (%), unless otherwise indicated. BMI=body-mass index. POP-SS=pelvic organ prolapse symptom score. ICIQ-UI SF=International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form. *Pelvic organ prolapse quantification (POP-Q) stage reported here was calculated at the analysis stage with a specially developed programme that used the nine individual POP-Q measurements recorded by the gynaecologist. On occasion this stage differed from that assigned by the gynaecologist that identified women's trial eligibility. †POP-SS: 0=no symptoms, 28=all seven symptoms all the time. ‡We defined faecal urgency as a sudden, irresistible need to have a bowel movement; faecal incontinence was any involuntary loss of faecal material. §ICIQ-UI SF score: 0=no incontinence, no interference with everyday life; 21=maximum leakage and interference. than in the control group had an improvement in their prolapse stage by 6 months (table 4), but this diff erence was not signifi cant (risk diff erence 7·5%, 95% CI -1·4 to 16·4, p=0·10; risk ratio 1·39, 95% CI 0·94-2·06, p=0·10). At 12 months, signifi cantly more women in the control group than the intervention group had received further treatment (table 4; risk diff erence 25·5%, 14·5-36·0, p<0·0001; risk ratio 2·1, 1·5-2·9, p<0·0001). We noted a similar uptake of surgery, pessary, and other non-trial treatments in the study groups at 12 months, but signifi cantly more women in the control group had had a physiotherapy referral for pelvic fl oor muscle training (table 4) .
Women were asked to report to what extent prolapse interfered with dimensions of their quality of life and about other symptoms (table 5) . At 6 months, scores in women in the intervention group were signifi cantly lower (ie, better) than those in women in the control group for all aspects of daily life, and sexual, bladder, and bowel function (except for faecal incontinence), but this fi nding was not evident at 12 months (table 5). The treatment eff ect at 12 months was consistent for all prespecifi ed subgroups. We recorded no signifi cant interactions between trial group and any of the subgroup terms in the model: prolapse stage I-III (p=0·38); prolapse type of most descended part anterior, posterior, or upper (p=0·61); age younger than 50 years or 50 years and older (p=0·29); and motivation for surgery as keen or wants to avoid (p=0·89).
The cost of the physiotherapy intervention was £170·24 on the basis of an hourly cost of £30·67 for a band 6 physiotherapist. 25 Trial physiotherapists reported that initial appointments took 80 min (60 min face-to-face plus 20 min of administration); follow-up appointments (maximum of four) took 40 min. For overheads such as the cost of the examination room, a fi gure of £16 per appointment was used. 26 On average women attended for 4·2 sessions of the possible fi ve; therefore, we applied an 84% uptake rate. On the basis of the questionnaire responses regarding further treatment received, and of published cost estimates of the various treatment courses (surgery £1044, 26 pessary £229·45, 27 Data are diff erence (95% CI) or n/N (%), unless otherwise indicated. POP-SS=pelvic organ prolapse symptom score. *Adjusted for baseline POP-SS, Pelvic organ prolapse quantifi cation (POP-Q) stage, centre, and whether or not the woman was motivated to have surgery. †POP-SS: 0=no symptoms, 28=all seven symptoms all the time. ‡The question about the number of days with symptoms had a seven-category response, from 0 (none of the time) to 6 (every day). We used the Mann-Whitney U test for the number of categories changed since baseline. ), the diff erence between the groups in mean cost of subsequent treatment was £38·63 (95% CI -41·95 to 126·41; p=0·34). The mean cost per woman in the control group was £306·86 (250·74-368·29) and per woman in the intervention group was £268·23 (210·35-333·59). Overall, the net cost of the intervention per woman was £170·24-£38·63=£131·61. This cost is set against a signifi cant diff erence between groups for the primary outcome. The net cost per one-point improvement in POP-SS was £131·61/1·52, or £86·59. When we consider the 95% CI around the diff erence in change in POP-SS from baseline (0·46-2·59), the cost per point improvement in POP-SS ranges from £51·81 to £286·11. When we consider the 95% CI around the net costs (£170·24-£126·41 to £170·24+£41·95) the cost per point improvement on POP-SS ranges from £28·84 to £139·60.
Discussion
Our fi ndings show a greater reduction in prolapse symptoms at 12 months in women who underwent pelvic fl oor muscle training than in the control group. This diff erence was both statistically signifi cant and of a magnitude that would be important to women, because it exceeded the minimally important change for the POP-SS. 29 This fi nding was supported by an increase in uptake of supplementary treatments (mainly pelvic fl oor muscle training) in the control group after 6 months, showing a residual need; a reduced prevalence of each individual prolapse symptom, and of bladder, bowel, and sexual symptoms; and a better quality of life in the intervention group after 6 months of muscle training. Furthermore, women in the intervention group were more likely to report that their prolapse was "better" at both 6 months and 12 months. Although more women in the intervention group had improvement in prolapse stage, this result did not diff er signifi cantly between the groups. Subgroup analyses showed that these fi ndings of eff ectiveness held irrespective of prolapse stage or type, or the woman's age or attitude towards having surgery. Because of the high degree of uptake of some form of pelvic fl oor muscle training in the control group before the primary outcome assessment at 12 months, and the absence of evidence of diff erential use of other non-training interventions, the intention-to-treat treatment eff ect estimate could be an underestimate of the benefi t associated with pelvic fl oor muscle training at 12 months. Therefore, we are confi dent that the signifi cant treatment eff ects reported represent real eff ects that are of importance to women and clinicians. The fi nding that at 12 months, women in the control group were as likely to be exercising as were those in the intervention group might partly be explained by the uptake of physiotherapy in the control group. That almost 80% of women in the intervention group were still exercising at 12 months is encouraging, because longterm adherence is an important consideration for the eff ectiveness of this intervention.
The net cost of the intervention was about £130 per woman. The main determinant of the net cost of the intervention is its provision. The main area of uncertainty is the longer-term eff ect of pelvic fl oor muscle training on the need for subsequent treatments such as pessaries, Data are median (IQR) or n/N (%), unless otherwise indicated. Women were asked to answer questions in relation to the last 4 weeks. ICIQ-UI SF=International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form. *Prolapse-related interference scores range from 0 (not at all) to 10 (a great deal). †Mann-Whitney U test done on the ordinal response. ‡ICIQ-UI SF score: 0=no incontinence, no interference with everyday life; 21=maximum leakage and interference. §We defi ned faecal urgency as sudden, irresistible need to have a bowel movement; faecal incontinence was any involuntary loss of faecal material. Table 5 : Self-reported eff ect of prolapse symptoms, and prevalence of urinary and bowel symptoms at 6 months and 12 months physiotherapy, and surgery; our results are based on the trial follow-up period and we cannot exclude the possibility that treatments have been delayed rather than avoided. Our sensitivity analyses showed plausible ranges around our results; however, reasons exist for believing that the increased costs are unlikely-namely that expenditure on the intervention is a once-only event, as such all costs have been incurred and the benefi ts in terms of reduced symptoms and treatments avoided are likely to continue to accrue over time. In the assumption that women in the intervention group gained 10% on their quality of life for a year because of the intervention, the cost per qualityadjusted life-year (QALY) gained is about £16 000. This level of cost per QALY is commonly accepted as worthwhile by organisations such as the National Institute for Health and Clinical Excellence in the UK.
The main strengths of our trial were its size, rigour, and pragmatic design, with the intervention being relevant to UK NHS practice, and potentially to other similar health systems worldwide; furthermore, the outcomes were woman-centred. Participants' compliance with trial processes and the intervention were generally high. Unlike other trials in this specialty, our main focus was the prolapse symptoms that led women to seek treatment, and which we used to measure treatment success.
In terms of limitations, we achieved 88% of our target sample size of 506, and noted a lower rate of questionnaire response than expected at 12 months, despite postal and telephone reminders. However, because the SD of the POP-SS was smaller than originally assumed, we nevertheless had suffi cient power to identify important diff erences. We noted no evidence of diff erential dropout because the response rate was similar in both groups, and results were also robust to missing data. Not all women had a prolapse assessment at 6 months; therefore there was also attrition in the POP-Q responses. This attrition might have contributed to the non-signifi cant POP-Q fi nding. We noted signifi cant crossover of women in the control group to the intervention group due to their uptake of pelvic fl oor muscle training after 6 months, which makes interpretation of the fi ndings more challenging. A further limitation is the short follow-up period of 12 months. Because of natural fl uctuation in prolapse symptoms and the eff ect of diff erent treatment modalities, clinical and cost diff erences between the groups might be expected to change with time. Included women were treatment-naive and presented for treatment for the fi rst time. However, pelvic fl oor muscle training might also be eff ective for enhancement of surgical or pessary treatment, or for use after surgical failure, or shortly after childbirth, and these situations need further research. In the economic analysis we did not estimate QALYs gained because fi ndings from our pilot work showed that the SF-12 was insensitive to meaningful changes in prolapse symptoms in this population. Therefore, decision makers should interpret the results on the basis of a careful reading of the symptoms women suff ered and the extent to which these symptoms were relieved. The paucity of other economic studies in this specialty makes comparing of results diffi cult; we look forward to future studies that provide comparisons for these results.
Six other randomised studies have been published to date comparing pelvic fl oor muscle training with a control intervention. 12, [30] [31] [32] [33] [34] Three of these trials are pilot trials, which makes the drawing of conclusions from their fi ndings problematic on the basis of their developmental nature and small sample sizes. 12, 30, 31 Three other full-sized trials have been published. [32] [33] [34] The Piya-Anant trial 32 had methodological limitations and a high risk of bias, and cannot reliably contribute to the evidence base. No information was provided about the processes of random sequence generation or allocation concealment, the investigators did not report about attrition and selectively reported about only a subgroup of the women randomised, and uncertainty existed as to whether the analysis was intention to treat. Of the remaining two trials, the Braekken single-centre trial 33 of pelvic fl oor muscle training versus control randomly assigned 109 women with stage I-III prolapse, of which a subgroup of only 69 (63%) women were symptomatic and hence similar to our population. The very intensive training regimen consisted of weekly appointments for 3 months, followed by bi-weekly appointments for 3 months-a treatment model that would not be possible to deliver in the UK and many other countries because of the restricted availability of specialist physiotherapy resource within their health services. Kashyap and colleagues 34 reported a single-centre trial in women with stage I-III prolapse, which compared taught pelvic fl oor muscle training plus a self-instruction manual (n=70) with the self-instruction manual alone as the control intervention (n=70). One person delivered the training intervention to all women. The content of the manual was not described and therefore what written instruction the control group received is unclear. More importantly, four women transferred from the control group to the training plus manual group; in which group these women were analysed is unclear. Until this point is clarifi ed, the results have restricted use.
Both Braekken and colleagues 33 and Kashyap and colleagues 34 reported symptom benefi t from pelvic fl oor muscle training. Braekken and colleagues analysed the subgroup of women with symptoms at baseline and reported that women who had received muscle training were more likely than women in the control group to have reduced frequency of prolapse symptoms (74% vs 31%) and reduced bother of symptoms (67% vs 42%). Kashyap and colleagues reported a signifi cantly greater mean reduction in POP-SS score after the intervention for the muscle training plus manual group compared with the control group (2·99 vs 1·25). Neither trial sought evidence about longer term outcomes or the eff ect on the uptake of other treatments.
Braekken and colleagues 33 also reported that pelvic fl oor muscle training improved POP-Q stage: 19% of women in the intervention group had an improved stage versus 8% in the control group (11% risk diff erence). Our fi nding for POP-Q was non-signifi cant, but of a similar size. The most likely reason for the non-signifi cant fi nding in our trial is that the study was not powered to show a diff erence for this outcome. Data for change in the POP-Q or prolapse stage in Kashyap and colleagues' trial were not adequately reported to allow comparison. 34 We chose symptom change as our primary outcome measure. This endpoint is usually the driver for individuals seeking treatment for prolapse and is hence the most important outcome for women. That little correlation exists between stage of prolapse and the prolapse symptoms ascribed to it is increasingly recognised. 35, 36 Therefore, and as we recorded, that an improvement in symptoms does not necessarily correspond to an improvement in stage is not surprising. 45% of women in the control group in our study reported that their prolapse was better at 12 months. This fi nding is partly because about half of these women had received further treatment for prolapse by this timepoint. Although signifi cantly more women in the intervention group than the control group reported that their prolapse was better, the remaining participants reported no change or worse prolapse. Thus, a substantial group of women did not benefi t. One potential reason for this fi nding is that a more intensive intervention might be needed for some women. Another reason is that some types or stages of prolapse do not respond to pelvic fl oor muscle training as well as do others, and hence, improved selection of women for training might be needed. Although our subgroup analyses did not support these hypotheses, the analyses were exploratory and underpowered to draw fi rm conclusions.
Prolapse can regress with time, which could partly explain the improvement we noted. Three studies of the epidemiology of prolapse concluded that prolapse can both progress and regress. [37] [38] [39] Handa and colleagues' 37 and Bradley and colleagues' 38 studies assessed change in severity of prolapse, but in populations older than our own. The study by Miedel and colleagues 39 is most relevant for comparison because it examined both symptoms and stage of prolapse over time in women with a mean age of 56 years. Their fi ndings show that 44% of stage I prolapses had regressed to stage 0, 24% of stage II showed regression, and 64% (95% CI 56-72) of women had a reduction in symptoms by 5 years. However, the study population was mainly nonconsulting women identifi ed by a positive questionnaire response to "a feeling of a vaginal bulge", rather than women who were actively seeking treatment for prolapse. As the investigators mentioned, results cannot be automatically generalised to patients who present to health-care services. Therefore, we do not know to what extent women in our trial naturally improved. However, we would expect that any natural regression or progression would happen equally in both groups by virtue of the group allocation, and hence the noted signifi cant diff erences between the groups must be due to the intervention.
Our trial is the largest, rigorous, pragmatic multicentre trial of pelvic fl oor muscle training for prolapse, with the longest follow-up, and as such provides the necessary evidence to support changes in clinical practice (panel). However the resource implications of implementation of these fi ndings should be considered. The physiotherapists delivering the trial intervention were specialists in women's health; their numbers are few and their workload is large, presently consisting of mainly the management of urinary incontinence. With the establishment of an evidence-base for pelvic fl oor muscle training for the management of prolapse, health-care providers will need to invest in extra resources to ensure that a similar service can be provided for women with prolapse. Additionally, beyond the clinical arena, the role of pelvic fl oor muscle exercises for alleviation of prolapse symptoms is an important public health message that should be shared widely among women of all ages.
We conclude that pelvic fl oor muscle training should be recommended for the conservative management of prolapse. Eff ectiveness of such training in the long term, in women who have had previous prolapse surgery, in conjunction with pessary use, and within populations of women with diff erent types or combinations of prolapse, should be investigated further. ) with the search terms: cystocele, urethrocele, rectocele, vault prolapse, uterine prolapse, vaginal prolapse, pelvic organ prolapse, pelvic fl oor. We did not impose any language or other restrictions in any of the searches. Four included trials compared pelvic fl oor muscle training with a control intervention, 12, 30, 32, 33 but two were at signifi cant risk of bias; 30, 32 of the remaining two trials, one was the pilot study preceding the current trial. 12 Prolapse symptoms were measured diff erently in the three trials where this was reported; 12, 30, 33 however, all three reported greater improvement in symptoms in the training group than the control group. Restricted data from the two trials with low risk of bias 12, 33 suggested that pelvic fl oor muscle training increases the chance of an improvement in prolapse stage compared with no training.
Interpretation
Our trial is the largest, rigorous, pragmatic trial of pelvic fl oor muscle training versus control for prolapse, and as such provides important robust evidence to inform clinical practice. Our fi ndings confi rm those of other smaller or less rigorous studies that such training is benefi cial in terms of reducing women's prolapse symptoms. These fi ndings have implications for a range of health-care professionals who care for women with prolapse and for women themselves. Long-term benefi ts should be investigated, as should the eff ects in specifi c subgroups.
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